On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

Presbyopia is an age-related refractive condition marked by a gradual decline in near vision, typically emerging between ages ...

Wolfe Research initiated coverage of AbbVie (ABBV) with an Outperform rating and $205 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

The pharma is trying to win court backing to pay hospitals rebates for two drugs in the 340B drug discount program, instead ...

AbbVie’s stock price fell over 12% after emraclidine, an investigational anti-psychotic being evaluated for the treatment of ...

Meacham covers the Healthcare sector, focusing on stocks such as AbbVie, Pfizer, and Vertex Pharmaceuticals. Royalty Pharma has an analyst consensus of Strong Buy, with a price target consensus of $48 ...

It also profiles the leading makers of antibody drugs, such as AbbVie and Amgen. The report focuses on how monoclonal ...

November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY® (e ...